{"id":1851,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2000-07-14","marketCap":1028.63,"name":"Cassava Sciences Inc","phone":"15125012444.0","outstanding":42.17,"symbol":"SAVA","website":"https://www.cassavasciences.com/","industry":"Pharmaceuticals"},"price":28.7451,"year":2023,"month":12,"day":14,"weekday":"Thursday","title":"Impact of Corporate Earnings Reports on Cassava Sciences Inc Stock's Price Movements","date":"2023-12-14","url":"/posts/2023/12/14/SAVA","content":[{"section":"Earnings Report 1: Q2 2021","text":"Cassava Sciences Inc released its Q2 2021 earnings report on July 29, 2021. The company reported revenue of $0.3 million, primarily comprised of collaboration revenue. This represented a significant increase from the previous year's Q2 revenue of $0.1 million. The net loss for the quarter was $9.1 million, compared to a net loss of $8.7 million in Q2 2020. Despite the increase in revenue, the company's stock price experienced a slight decline in the days following the earnings report, possibly due to market expectations not being fully met."},{"section":"Earnings Report 2: Q3 2021","text":"On November 4, 2021, Cassava Sciences Inc released its Q3 2021 earnings report. The company reported $1.3 million in revenue for the quarter, representing a significant increase from the previous year's Q3 revenue of $0.2 million. The net loss for the quarter was $2.4 million, compared to a net loss of $3.6 million in Q3 2020. The earnings report was well-received by investors, and the stock price experienced a notable increase in the days following the report's release. The positive revenue growth and reduced net loss likely contributed to the upward movement in the stock price."},{"section":"Earnings Report 3: Q4 2021","text":"Cassava Sciences Inc released its Q4 2021 earnings report on March 3, 2022. The company reported $0.4 million in revenue for the quarter, marking a slight increase from the previous year's Q4 revenue of $0.3 million. The net loss for the quarter was $7.6 million, compared to a net loss of $5.4 million in Q4 2020. The earnings report led to a moderate decline in the stock price in the days following the release. The increase in net loss and the relatively flat revenue growth compared to the previous year's quarter may have contributed to the decrease in stock price."},{"section":"Earnings Report 4: Q1 2022","text":"On May 9, 2022, Cassava Sciences Inc released its Q1 2022 earnings report. The company reported revenue of $1.9 million, representing a significant increase from the previous year's Q1 revenue of $0.2 million. The net loss for the quarter was $2.1 million, compared to a net loss of $1.6 million in Q1 2021. The earnings report was well-received by investors, and the stock price experienced a notable increase in the days following the report's release. The substantial revenue growth and reduced net loss likely contributed to the positive impact on the stock price."},{"section":"Conclusion","text":"The analysis of recent earnings reports for Cassava Sciences Inc demonstrates that the company's stock price movements are influenced by the announced financial results. Positive revenue growth and reduced net losses tend to have a positive impact on the stock price, leading to an increase in value. Conversely, if the company fails to meet market expectations or experiences an increase in net losses, the stock price may decline. It is important to note that various factors beyond earnings reports, such as market conditions and investor sentiment, can also influence stock price movements."}],"tags":["CrossOver21","Long","Pharmaceuticals"],"news":[{"category":"company","date":1702483800,"headline":"Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days","id":124501338,"image":"","symbol":"SAVA","publisher":"Yahoo","summary":"Cassava Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 88.  The company earns the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group.","url":"https://finance.yahoo.com/m/b63bde7d-cc05-357c-acaf-5d7051499d36/cassava-sciences-stock-shows.html"},{"category":"company","date":1702390380,"headline":"Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders","id":124478726,"image":"https://s.yimg.com/ny/api/res/1.2/sjuFUQg1K1J1QPFjekLaqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","symbol":"SAVA","publisher":"Yahoo","summary":"Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of ChargeWarrants Are Expected to List and Trade on NasdaqWarrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (\"Cassava Sciences\" or the \"Company\") today announced a pro rata dividend distribution of warra","url":"https://finance.yahoo.com/news/cassava-sciences-announces-dividend-distribution-141300340.html"},{"category":"company","date":1702379880,"headline":"Cassava Sciences gains on dividend distribution","id":124465191,"image":"","symbol":"SAVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253473737"},{"category":"company","date":1702378800,"headline":"What You Missed On Wall Street This Morning","id":124460760,"image":"","symbol":"SAVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253449252"},{"category":"company","date":1702375500,"headline":"Cassava Sciences call volume above normal and directionally bullish","id":124465193,"image":"","symbol":"SAVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253374696"},{"category":"company","date":1702372680,"headline":"Blue Bird Posts Upbeat Results, Joins Oil-Dri Corporation of America, Eagle Bulk Shipping And Other Big Stocks Moving Higher On Tuesday","id":124462606,"image":"","symbol":"SAVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253312618"},{"category":"company","date":1702350840,"headline":"What You Missed On Wall Street On Tuesday","id":124467761,"image":"","symbol":"SAVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253809245"},{"category":"company","date":1702342980,"headline":"Why Is Cassava Sciences (SAVA) Stock Up 15% Today?","id":124465197,"image":"","symbol":"SAVA","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253620883"},{"category":"company","date":1702294860,"headline":"10 Health Care Stocks With Whale Alerts In Today's Session","id":124439312,"image":"","symbol":"SAVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251642760"},{"category":"company","date":1702289220,"headline":"Biotech Alert: Searches spiking for these stocks today","id":124439300,"image":"","symbol":"SAVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251513350"},{"category":"company","date":1702081868,"headline":"Why Cassava Sciences Stock Soared Today","id":124405369,"image":"https://s.yimg.com/ny/api/res/1.2/q4.VS73kcHwc.Q_n47oY2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/59f8e08a04c9a1c9e3eb0a0be05c0c7a","symbol":"SAVA","publisher":"Yahoo","summary":"Ambitious biotech Cassava Sciences (NASDAQ: SAVA) had a fine Friday on the stock market, with its shares closing more than 17% higher.  Cassava, which concentrates its efforts on treatments for Alzheimer's disease, said that it had appointed three new members to its board of directors.  Of the trio, two are seasoned veterans in the healthcare industry, and the third has notable experience in cybersecurity and emergency-response management.","url":"https://finance.yahoo.com/m/cc328f2b-f8e5-3d7d-b24b-97e8a0466365/why-cassava-sciences-stock.html"},{"category":"company","date":1702027109,"headline":"Cassava Sciences Appoints Three New Members to its Board of Directors","id":124387059,"image":"","symbol":"SAVA","publisher":"Finnhub","summary":"AUSTIN - Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the appointment of three new members to its Board of Directors, effective...","url":"https://finnhub.io/api/news?id=1ac5310a2c47786df9a4f8311f693f10cedbbddffed89fc7ba096d38158551b9"},{"category":"company","date":1701982860,"headline":"Cassava Sciences Appoints Three New Members to its Board of Directors","id":124374313,"image":"https://s.yimg.com/ny/api/res/1.2/sjuFUQg1K1J1QPFjekLaqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","symbol":"SAVA","publisher":"Yahoo","summary":"Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M\u0026A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted i","url":"https://finance.yahoo.com/news/cassava-sciences-appoints-three-members-210100761.html"},{"category":"company","date":1701882211,"headline":"Cassava Sciences - How To Interpret 3 'Positive' Updates Shared In Q3","id":124344651,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1592634041/image_1592634041.jpg?io=getty-c-w1536","symbol":"SAVA","publisher":"SeekingAlpha","summary":"Cassava's stock price has experienced significant losses, down 40% on a 12-month basis and 29% year-to-date. Click here to read an analysis on SAVA stock now.","url":"https://seekingalpha.com/article/4656409-cassava-sciences-how-to-interpret-3-positive-updates-shared-in-q3"},{"category":"company","date":1701748690,"headline":"Alzheimer's Disease Drug Development: Another Lost Year","id":124297925,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295875196/image_1295875196.jpg?io=getty-c-w1536","symbol":"SAVA","publisher":"SeekingAlpha","summary":"Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Click here for a detailed review.","url":"https://seekingalpha.com/article/4655976-alzheimers-disease-drug-development-another-lost-year"},{"category":"company","date":1701661140,"headline":"Bullish Two Hundred Day Moving Average Cross - SAVA","id":124288895,"image":"","symbol":"SAVA","publisher":"Market News Video","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241048647"}]}